Original Article

Outflow facility efficacy of five drugs in enucleated porcine eyes by a method of constant-pressure perfusion

Ning Li*, Hui-Min Shi*, Lin Cong, Zhao-Zeng Lu, Wen Ye, Yu-Yan Zhang

Department of Ophthalmology, Huashan Hospital of Fudan University, Shanghai 200040, China. *Equal contributors.

Received March 27, 2015; Accepted May 11, 2015; Epub May 15, 2015; Published May 30, 2015

Abstract: This study aimed to characterize a technique that assesses the outflow facility (C) efficacy of five kinds of IOP-lowering drugs commonly used clinically in enucleated porcine Eyes. Eyes were perfused at 15 mmHg with GPBS first to establish the baseline outflow facility (C0). Then the anterior chamber contents were exchanged for GPBS with corresponding concentration eye drops (4.9×10^3 nM Brimonidine, 41.1 nM Latanoprost, 3.4×10^3 nM Levobunolol, 3.0×10^3 nM Brinzolamide, 8.3×10^3 nM Pilocarpine) in five groups (n = 6 each), while 6 eyes received GPBS alone as control. The mean stable facility obtained after drug administration (C1) was continuously recorded. The changes between C0 and C1 (∆C = C1 - C0) were analyzed. Finally, for drugs among the five experiment groups with statistical significance, the concentration was reduced 3 times, otherwise the drugs’ concentration was increased to 10 times to confirm its effectiveness further using the same methods (n = 6 each). We found that the average baseline outflow facility was 0.24±0.01 μl·min⁻¹·mmHg⁻¹. C increased significantly in Brimonidine and Latanoprost groups, even the concentration of Brimonidine and Latanoprost was decreased 3 times (P < 0.05). However, there was no significantly increase in Levobunolol, Brinzolamide, Pilocarpine and control group (P > 0.05), but when drugs’ concentration was increased to 10 times, the C value of Pilocarpine decreased significantly (P = 0.04). No significant washout effects in porcine eyes were observed. To conclude, outflow facility efficacy of five drugs in enucleated porcine eyes may provide a reference for clinical medicine. A constant-pressure perfusion technique should be useful to evaluate effect of pharmacologic agents or surgical manipulations on aqueous humor dynamics.

Keywords: Aqueous humor outflow facility, ocular perfusion, porcine eyes, ocular hypotensive drugs

Introduction

Glaucoma is characterized by a progressive loss of retinal ganglion cells, a characteristic optic neuropathy and patterns of visual field loss in the more advanced stages. It is a multifactorial disease with several recognized risk factors, of which elevated intraocular pressure (IOP) is a primary contributing factor caused by increased aqueous outflow resistance [1, 2]. Lowering IOP by medications or surgery is the only therapeutic modality currently available. Therefore, to precisely describe and understand the regulation of IOP and its mechanism in the eyes is very important for glaucoma research. Notably, the source of increased outflow resistance in primary open angle glaucoma (POAG) has not yet been identified. Studies of the hydrodynamic and morphological correlation of decreasing outflow facility (C), which is defined as the reciprocal of the resistance to aqueous humor outflow as it exits the anterior chamber of the eye, associated with acute and chronic experimental elevation of IOP, have partly improved our understanding of the pathogenesis of this disease [3, 4]. For the screening of potential new compounds, five in vitro models have been used: monolayer cell culture, whole eyes, explant culture, and anterior segment culture; both stationary and perfusion systems. In the case of perfusion techniques, IOP and one-way flow of aqueous can be maintained [5]. In the present study, total C is measured, which is equal to the arithmetic sum of trabecular outflow facility and uveoscleral outflow facility. By comparing C before (C0) and after (C1) IOP-lowering drug administration from the same eye, we try to assess the effects of
the five pharmacologic agents (Brimonidine, Latanoprost, Levobunolol, Brinzolamide, and Pilocarpine) on aqueous humor outflow facility, as well as to demonstrate the utility of this approach.

Due to the anatomical differences between humans and animals, human eyes would constitute the most relevant test material in outflow studies; however, their use is limited by their difficult availability. Monkey, bovine, and porcine eyes have been used in whole-eye studies [4-12]. Many previous studies with porcine eyes have shown that the domestic pig is suitable for a variety of ophthalmologic studies [7, 8]. The porcine eye was chosen for this study because of its easy availability and low costs. The anterior chamber volume was 300 μl and the globe size was almost equal to the human eye. In addition, the porcine eye contains a shallow scleral sulcus with a wedge-shaped mass of corneoscleral tissue comparable in size to human trabecular meshwork (TM) [8]. Ultrastructural investigations have indicated that subendothelial regions and the cribriform of porcine TM have an architecture similar to that of primate TM [12].

In this study, we use a rapid constant-pressure perfusion technique to measure the outflow facility (C) efficacy of five kinds of eye drops (Brimonidine, Latanoprost, Levobunolol, Brinzolamide, Pilocarpine) commonly used clinically in porcine Eyes. Though the analysis of the results, may it can provide a reference for clinical medicine, and to assess whether this experimental approach can be useful to evaluate effects of pharmacologic agents or surgical manipulations on aqueous humor dynamics in porcine and other animal models.

**Methods**

**Materials**

Animal procedures were conducted in compliance with the association for research in vision and ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.

Sixty-six fresh enucleated porcine eyes were obtained from a local abattoir (Jiading, Shanghai, China), the pigs were 4-5 months old, weighing approximately 70 kg. The eyes delivered were delivered to our laboratory within 3 hours postmortem. Eyes with discernible damage or accumulated blood in the limbus or anterior chamber (AC) were excluded. The perfusate was Dulbecco’s phosphate-buffered saline (Ph = 7.3; Invitrogen, Grand Island, NY) containing 5.5 mM D-glucose (collectively referred to as GPBS) that was passed through a 0.2 μm cellulose acetate filter prior to use. 0.15% Brimonidine (Allergan, USA); 0.005% Latanoprost (Pfizer Manufacturing Belgium NV); 0.5% Levobunolol (Allergan, USA); 2% Brinzolamide (Alcon Laboratories Ltd, UK); Pilocarpine (Akorn, USA).

**Perfusion procedure**

Details of the mechanical setup of the perfusion system were described previously [4]. Briefly, the perfusion system consisted of a per-
Outflow facility efficacy of five drugs

Table 1. Summary of facility measurements, before and after drug treatments (mean ± SEM, μl·min⁻¹·mmHg⁻¹, n = 6)

<table>
<thead>
<tr>
<th>Group</th>
<th>C₀</th>
<th>C₁</th>
<th>ΔC</th>
<th>ΔC/ΔC₀×100%</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPBS</td>
<td>0.25±0.01</td>
<td>0.24±0.03</td>
<td>-0.01±0.02</td>
<td>-5.22±6.75</td>
<td>0.600</td>
</tr>
<tr>
<td>Brimonidine</td>
<td>0.25±0.02</td>
<td>0.33±0.04</td>
<td>0.07±0.02</td>
<td>26.65±6.32</td>
<td>0.010*</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>0.24±0.03</td>
<td>0.37±0.04</td>
<td>0.12±0.02</td>
<td>54.24±11.5</td>
<td>0.001*</td>
</tr>
<tr>
<td>Levobunolol</td>
<td>0.24±0.02</td>
<td>0.25±0.02</td>
<td>0.01±0.01</td>
<td>4.07±4.45</td>
<td>0.390</td>
</tr>
<tr>
<td>Brinzolamide</td>
<td>0.22±0.01</td>
<td>0.23±0.02</td>
<td>0.01±0.02</td>
<td>1.23±6.79</td>
<td>0.770</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>0.24±0.02</td>
<td>0.25±0.01</td>
<td>0.01±0.01</td>
<td>2.32±6.06</td>
<td>0.380</td>
</tr>
</tbody>
</table>

※5.5 mM GPBS and GPBS with corresponding concentration eye drops (4.9×10⁻³ nM Brimonidine, 4.11 nM Latanoprost, 3.4×10⁻³ nM Levobunolol, 3.0×10⁻³ nM Brinzolamide and 8.3×10⁻³ nM Pilocarpine). For 4.9×10⁻³ nM Brimonidine and 4.11 nM Latanoprost showed statistical differences between C₀ and C₁, their concentration was reduced 3 times, while other drugs concentration was improved 10 times to confirm its effectiveness further. Pre-operation (C₀), Post-operation (C₁); P < 0.05.

Table 2. Summary of facility measurements, before and after drug treatments (mean ± SEM, μl·min⁻¹·mmHg⁻¹, n = 6)

<table>
<thead>
<tr>
<th>Group</th>
<th>C₀</th>
<th>C₁</th>
<th>ΔC</th>
<th>ΔC/ΔC₀×100%</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPBS</td>
<td>0.25±0.01</td>
<td>0.24±0.03</td>
<td>-0.01±0.02</td>
<td>-5.22±6.75</td>
<td>0.600</td>
</tr>
<tr>
<td>Brimonidine</td>
<td>0.26±0.01</td>
<td>0.30±0.02</td>
<td>0.04±0.01</td>
<td>16.15±5.48</td>
<td>0.025^§</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>0.26±0.02</td>
<td>0.32±0.02</td>
<td>0.06±0.01</td>
<td>22.83±5.57</td>
<td>0.005^§</td>
</tr>
<tr>
<td>Levobunolol</td>
<td>0.26±0.02</td>
<td>0.28±0.02</td>
<td>0.02±0.01</td>
<td>5.27±3.18</td>
<td>0.157</td>
</tr>
<tr>
<td>Brinzolamide</td>
<td>0.24±0.02</td>
<td>0.26±0.03</td>
<td>0.02±0.01</td>
<td>8.62±7.20</td>
<td>0.302</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>0.24±0.02</td>
<td>0.22±0.02</td>
<td>-0.02±0.01</td>
<td>-10.10±2.22</td>
<td>0.004^§</td>
</tr>
</tbody>
</table>

※5.5 mM GPBS and GPBS with corresponding concentration eye drops (4.9×10⁻³ nM Brimonidine, 4.11 nM Latanoprost, 3.4×10⁻³ nM Levobunolol, 3.0×10⁻³ nM Brinzolamide and 8.3×10⁻³ nM Pilocarpine). Pre-operation (C₀), Post-operation (C₁); P < 0.05.

Sixty-six enucleated porcine eyes were randomly divided into eleven groups. First, all eyes were perfused at 15 mmHg constant pressure with GPBS at least 30 minutes to establish a stable baseline C₀. The perfusion pressure was set by adjusting the height of the reservoir above the surface of the eye. Assuming an episcleral venous pressure of 8 to 10 mmHg, this perfusion pressure would simulate an in vivo IOP of 22 to 25 mmHg [9]. Then the anterior chamber contents were exchanged for GPBS with corresponding concentration eye drops (4.9×10⁻³ nM Brimonidine, 4.11 nM Latanoprost, 3.4×10⁻³ nM Levobunolol, 3.0×10⁻³ nM Brinzolamide and 8.3×10⁻³ nM Pilocarpine) in five groups (N = 6 each). We chose this concentration based on ciliary body and iris tissue con-
Outflow facility efficacy of five drugs

Figure 2. Changes in outflow facility between pre-operation, C₀ and post-operation, C₁. An significantly increase in C was observed in 4.9×10³ nM Brimonidine and 41.1 nM Latanoprost groups compared with their own baselines (n = 6, paired t-test, P < 0.05). In contrast, perfusion with 3.4×10³ nM Levobunolol, 3.0×10³ nM Brinzolamide, 8.3×10³ nM Pilocarpine, GPBS groups had no significant differences in outflow facility compared to their own baselines (n = 6, paired t-test, P > 0.05). No clear washout effect (i.e., a time-dependent increase in outflow facility) was observed (calculated as a mean of the hourly recorded stable outflow facilities) in the GPBS group (n = 6, paired t-test, P = 0.60). P < 0.05.

Figure 3. Changes in outflow facility between pre-operation, C₀ and post-operation, C₁. An significantly increase in C was observed in 4.9×10³/3 nM Brimonidine and 41.1/3 nM Latanoprost groups compared with their own baselines (n = 6, paired t-test, P < 0.05). In contrast, perfusion with 3.4×10⁴ nM Levobunolol, 3.0×10⁴ nM Brinzolamide groups had no significant differences in outflow facility compared to their own baselines (n = 6, paired t-test, P > 0.05), while, 8.3×10⁴ nM Pilocarpine showed statistical decrease in C (n = 6, paired t-test, P < 0.05). §P < 0.05.

The concentrations of five drugs observed in topically treated nonhuman primates [13-17], which is the same as Win's study [18]. While 1 group (N = 6) received GPBS alone as control. Finally, for drugs among the five experiment groups with statistically significant changes, the concentration was reduced 3 times, otherwise the drugs concentration was increased to 10 times to confirm its effectiveness further using the same methods. Because whether porcine eyes exhibit washout is still controversial [5, 9, 19], the control group was included to account for the washout effect. Finally, the subsequent perfusion of all eyes with corresponding perfusate was at a fixed volume (0.3 ml) and C₁ was continuously recorded throughout the experiment.

Statistical analysis

Statistical analysis was performed with statistical software SPSS (Version 17.0; SPSS Inc., USA). The data were expressed as mean ± SEM. The comparison of difference for outflow facility between C₀ and C₁ was done by a paired two-sample t-test, while the difference for outflow facility within the same drug (changes in ∆C and ∆C%) in different concentration was compared with independent t-test. P < 0.05 were considered to be statistically significant.

Results

Outflow facilities of the eleven groups were shown in Tables 1 and 2. The average baseline facility (C₀) was 0.25±0.01 μl·min⁻¹·mmHg⁻¹ (mean ± SEM) in control eyes tested at 15 mmHg. No significant washout effect (i.e., a time-dependent increase in outflow facility) was observed in the GPBS group (P = 0.60). In 4.9×10³ nM Brimonidine and 41.1 nM Latanoprost treatment groups, ∆Cprim₁ = 0.07±0.02 μl·min⁻¹·mmHg⁻¹ (26.65±6.32%), ∆Cent₁ = 0.12±0.02 μl·min⁻¹·mmHg⁻¹ (54.20±11.59%), C increased significantly in Brimonidine (P = 0.010) and Latanoprost (P = 0.001) groups compared with their own baselines (Figure 2), even the concentration of 4.9×10³ nM Brimonidine and 41.1 nM Latanoprost was decreased 3 times, it showed the same tendency statistical differences between C₀ and C₁ (P = 0.025, P = 0.005).
However, there was no significantly increase in 3.4×10^3 nM Levobunolol, 3.0×10^3 nM Brinzolamide, 8.3×10^3 nM Pilocarpine and the control group (P = 0.390, P = 0.770, P = 0.380 and P = 0.600), when drugs' concentration was increased to 10 times, Levobunolol, and Brinzolamide groups showed no statistical differences between C₀ and C₁ but high concentration of Pilocarpine decreased C significantly (P = 0.04) with ∆C_pilo = -0.02±0.01 μl·min⁻¹·mmHg⁻¹ (-10.10±2.22%) (Figures 3-5).

Discussion

In this study, we used an ex vivo method with the perfused porcine eye suitable for testing clinical antiglaucomatous drugs on aqueous humor outflow facility. In our study, the mean baseline outflow facility was 0.25±0.01 μl·min⁻¹·mmHg⁻¹ (mean ± SEM; n = 6) in control eyes perfused at 15 mmHg, which is very similar to the 0.25±0.01 μl·min⁻¹·mmHg⁻¹ reported by Vaajanen and his coworkers [5]. According to the literature, the basal outflow facility in the enucleated porcine eye has been between 0.25±0.01 and 0.50±0.20 μl·min⁻¹·mmHg⁻¹ [5, 9, 19-21]. Several reasons may partially explain these differences. Different body weight of pigs (70 kg in the present study versus 80 kg or some papers not described in detail) and regional differences of pig eyes sources (Asia in the present study versus Europe).

Animal models in all perfusion methods are associated with a time-dependent increase in outflow facility, which has not found in human eyes in vitro [22]. This phenomenon is referred to as washout, in accordance with the hypothesis that the progressive decrease in resistance is the result of a perfusion-induced washing away of extracellular material from the outflow pathway tissue [22, 23]. The typical washout effect in porcine eyes has been between 6% and 26% [5, 19, 24]. However, Wagner and coworkers [9] observed no significant washout effect in their porcine whole-eye studies. In our study, No significant washout effect (i.e., a time-dependent increase in outflow facility) was observed either (calculated as a mean of the hourly recorded stable outflow facilities) in the GPBS group (P = 0.60). We suggest that the subsequent perfusion at a
fixed volume (0.3 ml) and the total perfusion time in the GPBS group was therefore at most 180 minutes, the volume and time were not enough to cause washout effect, and also strong traction was carefully avoided during enucleation so as not to damage sensitive eye structures.

Five IOP-lowering glaucoma medications were evaluated for their effects on C in the enucleated porcine eyes. We confirmed that the prostaglandin FP agonist latanoprost (41.1 nM), the β-adrenergic agonist brimonidine (4.9×10^3 nM) increased C value by 54.20±11.59% and 26.65±6.32%, similarly to previous studies tested by topical ocular delivery of 1 to 2 drops of the drug formulations in mouse eye [25, 26], while, there was no significantly different increase in C value when perfusing the β-blocker levobunolol (3.4×10^3 nM), the carbonic anhydrase inhibitor brinzolamide (3.0×10^3 nM), and the cholinergic agonist pilocarpine (8.3×10^3 nM). These results are in agreement with the findings of Millar et al. Latanoprost is a selective FP receptor agonist and it has been reported to increase uveoscleral outflow by remodeling the extracellular matrix in the ciliary muscle and affect intracellular pathways that control cell contractility [27]. It may also increase the conventional outflow facility through changes in the TM [13]. In our study, the C value of latanoprost group significantly increased, followed by brimonidine group, even the concentration of 41.1 nM Latanoprost and 4.9×10^3 nM Brimonidine was decreased 3 times, it showed the same tendency statistical differences between Cps and C1 (22.83±5.57%, P = 0.025; 16.15±5.48%, P = 0.005). Levobunolol and brinzolamide are compounds known to suppress aqueous humor formation, accordingly, it was ineffective in the porcine eye in the concentration based on ciliary body and iris tissue concentrations observed in topicaly treated nonhuman primates, there was insignificant as though the concentration of the drugs (Levobunolol and brinzolamide) was improved 10 times in the absence of a functioning circulatory system. Topical application of pilocarpine onto the human glaucomatous eyes lowers IOP, most commonly accepted mechanism of action for muscarinics involves receptor-mediated contraction of the ciliary muscle. Ciliary muscle contraction presumably creates tension on the TM and surrounding tissues. This tension may ultimately effect an enlargement of the intertrabecular spaces, thereby resulting in a decreased resistance to aqueous fluid outflow and a subsequent decrease in IOP [28]. Another muscarinic agent, carbachol, has been shown to induce contraction in isolated TM strips [29]. This direct effect on the TM may very well contribute to a portion of the outflow action of this class of compounds. In our study, 8.3×10^3 nM pilocarpine perceived no alteration in C value with statistical significance at 15 mmHg, while 8.3×10^4 nM pilocarpine led to a significant decrease in measured outflow facility. Our findings predict that high concentration of pilocarpine decreased C by inducing a contractile response in trabecular meshwork cells without affecting uveoscleral outflow pathway because of the ciliary muscle poorly developed in nonprimates (such as pig, cat) and there is no clear anatomical connection between the ciliary muscle and the drainage tissues [12].

Techniques for measuring C value have been reported for more than 50 years. In the first report, Bărașy [30] described a two-level, constant-pressure perfusion technique for measuring C in the vervet monkey. In this technique, total C (Ctot) is measured, which is equal to the arithmetic sum of trabecular outflow facility (Ctot), uveoscleral outflow facility (Cus), and inflow facility (Cin). Since publication of paper, this approach for measuring C has been adapted for use in several other species-for example, human beings [1, 3, 22], the cynomolgus monkey [4, 23, 30], the pig [5, 7-9, 24], the bovine [6, 10, 11]. We applied the whole-globe perfusion system similar to that of Sit’s application in 1977 [32]. The advantages of a constant-flow perfusion method over the more traditional Bărașy’s constant-pressure perfusion technique are minimal cost and ease of data acquisition. In addition, the small size of the mouse eye with minute changes in fluid volume movement requires greater sensitivity and further magnifies the problem. For the constant-pressure perfusion used in the present
study, a strain gauge is not required, because flow is induced with a reliable micro dialysis perfusion pump at the desired pressures (we used 15 mmHg). The resultant pressure generated is determined with a pressure transducer with an output signal in volts (rather than micro-volts) with a baseline sufficiently stable for the study period. The apparatus can be set up in a limited bench space, elaborate vibration-damping and electrical shielding are unnecessary. The procedure is technically straightforward, with a low failure rate (~5%) once the necessary skills have been acquired. This method also allows determination of the pressure-flow rate relationship using several infusion flow rates. We point out that recent studies have successfully exploited this technique to demonstrate the potential role of pharmacologic agent in outflow facility [4, 6].

In summary, in this study, a constant-pressure perfusion technique was used to assess outflow facility efficacy of five drugs in enucleated porcine eyes which may provide a reference for clinical medicine. This experimental approach should be useful to evaluate effects of pharmacologic agents or surgical manipulations on aqueous humor dynamics in porcine and other animal models.

Acknowledgements

This work was supported by operating research grants from the Shanghai Pujiang Program 11PJ006.

Disclosure of conflict of interest

None.

Address correspondence to: Yu-Yan Zhang and Wen Ye, Department of Ophthalmology, Huashan Hospital of Fudan University, 12 Wulumuqi Middle Road, Shanghai 200040, China. Tel: +86-21-52887803; E-mail: yuyan8688@163.com

References

Outflow facility efficacy of five drugs

- Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995; 23: 708-712.
- Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995; 23: 708-712.
- Comparison of ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995; 23: 708-712.
- Comparison of ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995; 23: 708-712.